Please login to the form below
Nestl
This page shows the latest Nestl news and features for those working in and with pharma, biotech and healthcare.
Nestlé and Seres announce new partnership for C.diff microbiome therapeutic
The companies will jointly commercialise Seres’ investigational oral microbiome therapeutic in the US and Canada
Latest news
-
Nestlé is set to acquire Aimmune in deal worth $2.6bn
Aimmune’s Palforzia therapy is the only FDA-approved peanut allergy drug
-
2018 by Darwin
Nestl é Health Science and other companies.
-
Nestlé Health Science invests $145m in food allergy biotech
Aimmune Therapeutics' lead product is a phase III peanut allergy treatment
-
Nestlé Health Science buys medical device firm
Acquisition of UK's Phagenesis expected to be completed by 2019
More from news
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
HTTP ERROR 400
Problem accessing /s/search.html. Reason:
Unable to parse URI query
Powered by Jetty:// 9.4.z-SNAPSHOT
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- World Health Organization releases latest set of COVID-19 guidelines
- ASH 2022: bad blood but big advances
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- Microfoundations matter
- 5 ways we’re enhancing our services to support our clients in 2023
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- World Health Organization releases latest set of COVID-19 guidelines
- Digital technology: a significant change in healthcare innovation
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Nicki Muir moves from LEC Healthcare to The Purple Agency
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
